Skip to Content

Suven Life Sciences Clinical candidate SUVN-502 Being Presented at International Conference on Alzheimer’s Disease, ICAD-2008 at Chicago, USA

HYDERABAD, India July 7, 2008 – Several data presentations from Suven’s portfolio of investigational neuroscience new chemical entities (NCEs) would be presented at Alzheimer’s conference (ICAD) to be held at Chicago USA during July 27-31, 2008.   ICAD is the bi-annual conference of the Alzheimer’s association and more than ten thousand Neuro Scientists, clinicians, corporate from all over the world covering all the major Pharma and Academic research Institutions would attend this meeting. 

Suven would present the key biology data in animal models of cognition and brain microdialysis on SUVN-502, a potent, selective, brain penetrant and orally active 5-HT6 receptor antagonist for the symptomatic treatment of Alzheimer’s disease.  Suven scientists also presenting paper on new animal model for Alzheimer’s disease with dual blockade of cholinergic and glutametergic neural system induced memory impairment in rats. Alzheimer’s disease has a significant unmet medical need for which current treatment options are insufficient. Suven has a number of discovery programs in the area of cognition, focusing on novel approaches that may lead to the development of new therapies for patients.
Suven is committed to neuroscience research and for development of new treatments for neurological disorders. Suven’s discovery research focuses on Central Nervous System (CNS) disorders through novel mechanisms using small-molecule medicinal chemistry approaches. Suven’s CNS drug discovery scientists at Hyderabad, India are pursuing innovative ways to develop treatments for a variety of CNS disorders like Alzheimer's, Schizophrenia, Depression, Cognitive disorders, Sleep, Neurodegeneration and Obesity through CNS targets.

Suven Life Sciences, a Hyderabad based Life Sciences Company, pioneer in Contract Research And Manufacturing Services (CRAMS) since 1995 in its endeavor to become collaborative research partner (CRP) for global life science companies has embarked on new business model “Drug Discovery and Development Support Services” (DDDSS) with the onset of Intellectual Property Regime in India since January 2005. For more information on Suven, please visit our Web site at  

Risk Statement:
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive.

Posted: July 2008